Drug Profile


Alternative Names: CK 3579; HE 93

Latest Information Update: 19 Nov 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Helopharm
  • Class Class III antiarrhythmics; Imidazoles; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Arrhythmias

Most Recent Events

  • 19 Nov 1998 A preclinical study has been added to the pharmacodynamics section
  • 02 Sep 1998 No-Development-Reported for Arrhythmias in Canada (Unknown route)
  • 02 Sep 1998 No-Development-Reported for Arrhythmias in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top